2001
DOI: 10.1016/s0928-4257(01)00005-5
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

15
104
0
5

Year Published

2003
2003
2023
2023

Publication Types

Select...
6
2
2

Relationship

1
9

Authors

Journals

citations
Cited by 143 publications
(124 citation statements)
references
References 20 publications
15
104
0
5
Order By: Relevance
“…The dosage of ketoprofen used in the present study was 0.25 mg/ kg; we have previously reported that ketoprofen alone at a reduced dosage had caused mild to moderate gastric mucosal injuries, such as invasive erosions, without clinical signs in healthy dogs [31]. Tanaka et al have also reported that the gastric ulcerogenic property of NSAIDs cannot be accounted for solely by COX-1 inhibition; it requires the inhibition of both COX-1 and COX-2 [39]. One dog in the NC group exhibited the weakly positive fecal blood, and had small mucosal erosion in the pyloric antrum.…”
Section: Disccusionmentioning
confidence: 71%
“…The dosage of ketoprofen used in the present study was 0.25 mg/ kg; we have previously reported that ketoprofen alone at a reduced dosage had caused mild to moderate gastric mucosal injuries, such as invasive erosions, without clinical signs in healthy dogs [31]. Tanaka et al have also reported that the gastric ulcerogenic property of NSAIDs cannot be accounted for solely by COX-1 inhibition; it requires the inhibition of both COX-1 and COX-2 [39]. One dog in the NC group exhibited the weakly positive fecal blood, and had small mucosal erosion in the pyloric antrum.…”
Section: Disccusionmentioning
confidence: 71%
“…These observations indicate that, in contrast to the initial concept, COX-2 plays an important role in gastric mucosal defense. Accordingly to this, experimental studies have reported that inhibition of both COX-1 and COX-2 is required for NSAID-induced gastric injury Tanaka et al, 2001;Peskar et al, 2001) and therefore Coxibs markedly decrease but do not eliminate NSAIDs associated gastric and duodenal ulceration (Silverstein et al, 2000;Sostres et al, 2010). In fact, indomethacin and similar NSAIDs, which inhibit both isoforms of the COX enzyme, produce more severe damage in gastric tissue, even gastrointestinal bleeding, than more selective drugs (Delaney et al, 2007).…”
Section: Non-steroidal Anti-inflammatory Drugs (Nsaids)mentioning
confidence: 98%
“…10 min before L-NAME treatment. The histamine H 1 -receptor antagonist tripelennamine (Sigma), the nonselective cyclooxygenase inhibitors indomethacin (Sigma) and diclofenac (Sigma) (20,21), as well as 16,16-dimethyl prostaglandin E 2 (dm-PGE 2 ) (Cayman, Ann Arbor, MI, USA) were all administered (s.c.) 1 h before partial gastric vascular occlusion (22). The cyclooxynase (COX)-2 inhibitor rofecoxib (21,23) and the COX-1 inhibitor SC-560 (21,24), suspended in 0.5% CMC, were administered p.o.…”
Section: Agentsmentioning
confidence: 99%